Hims & Hers Health has expanded its convertible senior notes offering to $870 million, up from an initial $450 million. The 0% convertible notes are due in 2030 and are intended to provide the company with non-dilutive debt capital to support global expansion and investment in artificial intelligence. The increase in the offering size reflects confidence in the company's leadership position, with Hims & Hers holding approximately 50% market share in its category. Ahead of its first-quarter 2025 earnings report, the stock price rose from $27 to nearly $54 in post-market trading, demonstrating strong investor interest. Despite a slight pullback of 2.7% on one trading day, overall market sentiment remains bullish. Separately, TransMedics Group (ticker $TMDX) has experienced a 71% year-to-date gain, with high short interest and positive sentiment noted among investors.